Literature DB >> 23588720

Low-level viremia is associated with non-B subtypes in patients infected with HIV with virological success following HAART introduction.

Julien Saison1, Jean-Claude Tardy, Caroline Scholtes, Vinca Icard, Mary-Anne Trabaud, Thomas Perpoint, Christian Chidiac, René Ecochard, Patrice André, Tristan Ferry.   

Abstract

This prospective study aimed to determine factors associated with detection of very low-level viremia in patients infected with HIV-1 with virological success following HAART introduction. Fifty-seven patients, mostly (n = 51, 89%) treated with a protease inhibitor-based regimen, were included and followed for 2 years. Viral loads were monitored by Abbott m2000 RealTime HIV-1. Patients were classified as (i) HIV-RNA-negative if viral loads remained strictly undetectable (0 copies/ml), or (ii) HIV-RNA-positive if at least one HIV-1 RNA could be detected in 1-49 copies/ml during follow-up. At month 24, 44 patients (77%) were in the HIV-RNA-positive group, whereas 13 (23%) remained without very low-level viremia. Univariate analysis, Kaplan-Meier curves and the Cox proportional hazard model revealed that B subtype was the only predictor of belonging to the HIV-RNA-negative group (HR 3.98; 95% CI 1.08-14.7). This association needs to be confirmed. Further study of the reservoir and the mechanisms of viral latency according to HIV-subtype will also be necessary to develop new therapeutic strategies and eradicate HIV infection.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23588720     DOI: 10.1002/jmv.23553

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients.

Authors:  J Saison; T Ferry; J Demaret; D Maucort Boulch; F Venet; T Perpoint; F Ader; V Icard; C Chidiac; G Monneret
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

2.  Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.

Authors:  A Gonzalez-Serna; J E Min; C Woods; D Chan; V D Lima; J S G Montaner; P R Harrigan; L C Swenson
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

3.  Large-scale analysis of the prevalence and geographic distribution of HIV-1 non-B variants in the United States.

Authors:  Michael T Pyne; John Hackett; Vera Holzmayer; David R Hillyard
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

4.  Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study.

Authors:  Sivaporn Gatechompol; Lu Zheng; Yajing Bao; Anchalee Avihingsanon; Stephen J Kerr; Nagalingeswaran Kumarasamy; James G Hakim; Frank Maldarelli; Robert J Gorelick; Jorden L Welker; Jeffrey D Lifson; Mina C Hosseinipour; Joseph J Eron; Kiat Ruxrungtham
Journal:  Medicine (Baltimore)       Date:  2021-09-03       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.